NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a US-based clinical-stage biopharmaceutical company, announced on Tuesday that it has named Seth Van Voorhees PhD as its new chief financial officer and treasurer, effective 13 June 12022.

Dr Van Voorhees has held the position of CFO for PDS Biotechnology. He has spent 10 years as the CFO for Research Frontiers and for American Pacific. He has served in investment banking supporting chemical/pharmaceutical clients at Merrill Lynch, UBS Warburg, and Wasserstein Perella.

Dr Voorhees holds a PhD in chemistry from the University of Pennsylvania and an MBA from Columbia University.